Cardiff Oncology Inc CRDF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRDF is a good fit for your portfolio.
News
-
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
-
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?
-
Thinking about buying stock in Mind Medicine, Ocean Biomedical, Archer Aviation, Outlook Therapeutics, or Cardiff Oncology?
-
Thinking about buying stock in SoundHound AI, Kinross Gold, Nu Holdings, Cardiff Oncology, or Turtle Beach?
-
Thinking about buying stock in ShiftPixy, Minim, Cardiff Oncology, Laird Superfood, or Tenon Medical?
-
Thinking about buying stock in Recursion Pharmaceuticals, SoundHound AI, Cardiff Oncology, Mind Medicine, or Auddia?
-
Thinking about buying stock in SoundHound AI, Gulf Island Fabrication, Macy's, Rigetti Computing, or Cardiff Oncology?
-
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
Trading Information
- Previous Close Price
- $4.35
- Day Range
- $4.25–4.49
- 52-Week Range
- $0.94–6.42
- Bid/Ask
- $4.31 / $4.42
- Market Cap
- $194.79 Mil
- Volume/Avg
- 462,511 / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 398.24
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 32
- Website
- https://www.cardiffoncology.com
Comparables
Valuation
|
Metric
|
CRDF
|
CLDX
|
TYRA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.79 | 5.02 | 3.15 |
Price/Sales | 398.24 | 271.21 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CRDF
CLDX
TYRA
Financial Strength
|
Metric
|
CRDF
|
CLDX
|
TYRA
|
|---|---|---|---|
Quick Ratio | 7.19 | 13.69 | 13.27 |
Current Ratio | 7.41 | 13.87 | 13.80 |
Interest Coverage | — | — | — |
Quick Ratio
CRDF
CLDX
TYRA
Profitability
|
Metric
|
CRDF
|
CLDX
|
TYRA
|
|---|---|---|---|
Return on Assets (Normalized) | −37.66% | −30.49% | −22.50% |
Return on Equity (Normalized) | −42.26% | −33.19% | −23.73% |
Return on Invested Capital (Normalized) | −45.64% | −32.85% | −27.79% |
Return on Assets
CRDF
CLDX
TYRA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ycxrdvchf | Fmsmg | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Prtbldms | Svhkbl | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jfnywhmkz | Dtrsrhn | $98.8 Bil | |
MRNA
| Moderna Inc | Tqsfdky | Nvv | $38.8 Bil | |
ARGX
| argenx SE ADR | Qwpbmlwjt | Jqt | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Dgvxcjnhd | Clvwf | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rvwxyvhnr | Hjqtlv | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jrywgtnq | Kdyvvnl | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gktzvwfbd | Wnnkgp | $12.4 Bil | |
INCY
| Incyte Corp | Lpnllbkk | Mvvcgq | $11.9 Bil |